The Effect of Octreotide on Wound Drainage After Mastectomy (NCT05682209) | Clinical Trial Compass
CompletedPhase 4
The Effect of Octreotide on Wound Drainage After Mastectomy
Nigeria41 participantsStarted 2020-12-18
Plain-language summary
Patients who had mastectomy for breast cancer usually have drainage of some fluid from the site of surgery. This could be prolonged and may lead to other negative consequences after surgery. Octreotide could potentially reduce the amount of this drainage. In this study, patients were grouped into two: a first group that received octreotide injection and a second group that received a placebo. The study tested whether octreotide injection has any effect on the duration of fluid drainage from the surgery site after mastectomy for breast cancer.
Who can participate
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* All female breast cancer patients requiring modified radical mastectomy
Exclusion Criteria:
* All mastectomies without axillary clearance (simple and toilet mastectomies)
* Breast-conserving surgeries
* Patients undergoing immediate breast reconstruction after mastectomy
* Previous axillary surgery
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial tested octreotide specifically to reduce wound drainage and shorten the time until drain removal after mastectomy — since it's now completed, has my surgeon seen the results, and do they think those findings are relevant to my planned surgery?
2Octreotide is a hormone-blocking medication that's been around for a long time, so it's Phase 4 — but what side effects or risks did my doctor observe or read about in patients who received it after mastectomy, and would those risks be acceptable given my overall health?
3Since this study focused on seroma — fluid buildup under the skin after mastectomy — how likely am I personally to develop a seroma, and would something like octreotide even be worth considering for someone in my situation?
4If octreotide showed a benefit in reducing drain time after mastectomy, how would using it actually affect my recovery — would it mean fewer follow-up visits, earlier return to normal activity, or a lower chance of needing additional procedures to drain fluid?
5Are there other standard approaches my surgeon already uses to prevent seroma or manage drains after mastectomy, and how do those compare to what was tested in this trial?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Time to drain removal
Timeframe: 24 hours after surgery till a drain output of <40ml in the preceding 24hours